Enoxaparin in Posterior Circulation Stroke
Role in Acute Ischemic Stroke Treatment
- The American Heart Association recommends that enoxaparin is not used as primary treatment for posterior circulation stroke, as early anticoagulation has not demonstrated improved outcomes in terms of mortality or stroke recurrence 1, 2
- Early administration of enoxaparin in acute ischemic stroke is associated with increased risk of bleeding complications without clear evidence of benefit 3, 4
- The American College of Cardiology suggests that anticoagulation may be beneficial in patients with large-artery atherosclerosis (>50% stenosis), but this is not specific to posterior circulation 2, 3
VTE Prophylaxis in Stroke Patients
- Enoxaparin is recommended for VTE prophylaxis in immobilized stroke patients, with a standard prophylactic dose of 40 mg subcutaneously once daily 5, 6
- The American College of Chest Physicians recommends that VTE prophylaxis with enoxaparin should be initiated 24-48 hours after stroke onset to balance bleeding risk with VTE prevention 7, 6
Special Considerations
- Anticoagulants, including enoxaparin, are contraindicated during the first 24 hours after treatment with intravenous rtPA 2, 3
- For patients with renal impairment (CrCl <30 mL/min), dose adjustment or alternative anticoagulation with unfractionated heparin may be necessary 6
Combination Approach
- Early mobilization should be encouraged alongside pharmacological prophylaxis with enoxaparin 7, 6
- For patients at very high risk of VTE, a combination of mechanical prophylaxis and pharmacological prophylaxis with enoxaparin may provide optimal protection 7, 6